In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: Review of cytogenetic and molecular studies

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 32-38

  Hackanson, Björn ^a   Robbel, Christian ^a   Wijermans, Pierre ^b   Lübbert, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Chromosomal instability; Epigenetics; Hemoglobin F; p15INK4b; Silencing

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD9 ANTIGEN; DEPSIPEPTIDE; GAMMA GLOBIN; HEMOGLOBIN F; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MICROSOMAL AMINOPEPTIDASE; MYC PROTEIN; PROTEIN P15; BIOLOGICAL MARKER; CANCER TESTIS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; HISTONE DEACETYLASE INHIBITOR; HLA DR ANTIGEN; NUCLEOSIDE ANALOG; SODIUM PHENYLBUTYRIC ACID; UNCLASSIFIED DRUG; DNA; SODIUM PHENYLBUTYRATE; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BETA THALASSEMIA; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE LOCUS; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; KARYOTYPE; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA; THERAPY RESISTANCE; Y CHROMOSOME; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; DEMETHYLATION; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; EPIGENETICS; GENE IDENTIFICATION; GENE SILENCING; GENE TARGETING; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; IMMUNE RESPONSE; IMMUNOMODULATION; KARYOTYPING; LEUKEMIA CELL; LYMPHOCYTE DIFFERENTIATION; MOLECULAR GENETICS; MYELODYSPLASIA; PHENOTYPE; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RISK ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CPG ISLAND; DRUG ACTIVITY; DRUG EFFECT; EPSTEIN BARR VIRUS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; ACUTE DISEASE; ANIMAL; GENETIC EPIGENESIS; GENETICS; MOUSE; MYELOID LEUKEMIA;

ACUTE DISEASE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID; MICE; MYELODYSPLASTIC SYNDROMES;

EID: 29144467606     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0004-1     Document Type: Review

References (32)

1. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF (2004) Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22:1373-1381 10.1200/JCO.2004.04.185
2. Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2003) Methylation of p15 ink4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813-1819
3. Dahl C, Guldberg P (2003) DNA methylation analysis techniques. Biogerontology 4:233-250 10.1023/A:1025103319328
4. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P et al (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964 10.1182/blood.V100.8.2957
5. Fraga MF, Esteller M (2002) DNA methylation: A profile of methods and applications. BioTechniques 33:632-634, 636-649 12238773
6. Galm O, Wilop S, Lüders C, Jost E, Gehbauer G, Herman JG et al (2005) Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol (this issue) DOI: 10.1007/ s00777-005-0005-0
7. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW et al (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489-492 10.1126/science.1083558
8. Gore SD, Baylin SB, Dauses T, Grever MR, Jiemjit A, Manning J et al (2004) Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate. Blood 104: Abstract 469
9. Greenberg P, Cox C, LeBeau MM, Fenaux P et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 9058730
10. Haas PS, Wijermans P, Verhoef G, Lübbert M (2005) Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: Lack of evidence for induction of chromosomal instability. Leuk Res (Sept 12)
11. Issa JPJ, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640 10.1182/ blood-2003-03-0687
12. Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N et al (2000) 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379-2384 11001887
13. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E et al (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205 10.1016/0092-8674(95)90329-1
14. Ley TJ, DeSimone J, Anagnou NP, Keller GH, Humphries RK, Turner PH et al (1982) 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med 307:1469-1475 6183586
15. Liu ZJ, Maekawa M (2003) Polymerase chain reaction-based methods of DNA methylation analysis. Anal Biochem 317:259-265 10.1016/ S0003-2697(03)00169-6
16. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C et al (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349-357 10.1046/ j.1365-2141.2001.02933.x
17. Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P (2004) Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28:1267-1271 10.1016/j.leukres.2004.04.002
18. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L (2003) Epigenetic targets for immune intervention in human malignancies. Oncogene 22:6484-6488 10.1038/sj.onc.1206956
19. Matsuno N, Hoshino K, Nanri T, Kawakita T, Mitsuya H, Asou N (2004) Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics. Leukemia 18:1146-1148 10.1038/sj.leu.2403362
20. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R (2004) Modification of hematopoietic stem cell fate by 5-aza-2′-deoxycytidine and trichostatin A. Blood 103:4102-4110 10.1182/blood-2003-07-2431
21. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929 6206904
22. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R (1984) Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2:867-868 10.1016/ S0140-6736(84)90900-0
23. Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A et al (1989) 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4(Suppl 3):28-32 2483349
24. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L et al (2003) Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102:3865-3870 10.1182/blood-2003-05-1738
25. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V et al (2003) 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: A multi-mechanism therapeutic approach? Blood 101:4644-4646 10.1182/blood-2002-11-3458
26. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR et al (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl 1):21-29 7683352
27. Simon B, Lubomierski N (2004) Implication of the INK4a/ARF locus in gastroentero-pancreatic neuroendocrine tumorigenesis. Ann N Y Acad Sci 1014:284-299 10.1196/annals.1294.033
28. Tricot G, Vlietinck R, Boogaerts MA, Hendrickx B, De Wolf-Peeters C, Van den Berghe H et al (1985) Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60:19-32 3859319
29. Watson J, Staldman AW, Billelo FP (1948) The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 215:419-423
30. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA et al (2001) Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71:295-301 10.1016/S0003-4975(00)02421-8
31. Wijermans P, Lübbert, M, Verhoef G, Bosly A, Ravoet A, Andre M et al (2000) Low-dose 5-aza-2′deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A phase II multicenter study in elderly patients. J Clin Oncol 18:956-962 10694544
32. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol (in this issue) DOI: 10.1007/ s00277-005-0012-1